- Conditions
- Diabetes, Obesity
- Interventions
- Canagliflozin
- Drug
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 9,958
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Long QT Syndrome
- Interventions
- GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- West Bend, Wisconsin
- Conditions
- Primary Insomnia, Secondary Insomnia
- Interventions
- LY2624803, Placebo, zolpidem
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more
- Conditions
- Obesity With Diabetes, Overweight With Diabetes
- Interventions
- Ribupatide, Placebo
- Drug
- Lead sponsor
- Kailera
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 62
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 57 more
- Conditions
- HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
- Interventions
- Maraviroc, placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Opioid-use Disorder
- Interventions
- Cannabidiol (CBD) 600 mg, Placebo
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Tarzana, California
- Conditions
- Migraine
- Interventions
- Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers
- Interventions
- Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin
- Drug
- Lead sponsor
- AN2 Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Dementia, Cognitive Dysfunction, Alzheimer Disease, Lewy Body Disease, Frontotemporal Dementia
- Interventions
- Relational Research Recruitment and Engagement Intervention
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- COVID-19
- Interventions
- AT-001
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ankylosing Spondylitis
- Interventions
- ARRY-371797, p38 inhibitor; oral, Placebo; oral
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Omaha, Nebraska + 4 more
- Conditions
- Septicemia
- Interventions
- Initial Specimen Diversion Device (ISDD), Lab standard practice (LSP)
- Device
- Lead sponsor
- Magnolia Medical Technologies, Inc.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 971 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Hunger, Child Development, Social Isolation
- Interventions
- Self Empowerment Groups, Financial Empowerment, Matched Savings
- Behavioral
- Lead sponsor
- Center for Hunger-Free Communities
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- PTSD, Acute Stress Disorder, Trauma-related Stressor
- Interventions
- Placebo, Hydrocortisone
- Drug
- Lead sponsor
- Rachel Yehuda
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Dermatitis, Atopic
- Interventions
- Dupilumab, JNJ-95475939, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 13
- States / cities
- Fountain Valley, California • Los Angeles, California • Alpharetta, Georgia + 10 more
- Conditions
- Osteomyelitis, Diabetes, Amputation
- Interventions
- Rifampin, Riboflavin Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 843 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Loma Linda, California • Long Beach, California + 27 more
- Conditions
- Lupus Nephritis
- Interventions
- Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
- Conditions
- Obesity
- Interventions
- K-757, K-757 and open-label sitagliptin, Matching placebo to K-757, Matching placebo to K-757 and matching placebo to K-833, K-757 and K-833, Matching placebo to K-757, open-label sitagliptin
- Drug
- Lead sponsor
- Kallyope Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Healthy
- Interventions
- BLKR201, Placebo
- Drug
- Lead sponsor
- Formation Bio, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Heart Defects, Congenital
- Interventions
- Clopidogrel (SR25990), placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Up to 92 Days
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- HIV
- Interventions
- Suubi+Adherence, Bolstered Standard of Care
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 10 Years to 16 Years
- Enrollment
- 702 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo
- Drug
- Lead sponsor
- SynAct Pharma Aps
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania
- Conditions
- Ulcerative Colitis
- Interventions
- CurQD, Placebo, Vedolizumab
- Drug
- Lead sponsor
- Ryan C Ungaro
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Interventions
- Xanamem, Placebo
- Drug
- Lead sponsor
- Actinogen Medical
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more